1 in 3 Don't Respond to Antidepressants: What's Next

Report: Nearly 1 in 3 Patients Don't Respond to Antidepressants

Standard antidepressants fail to work for close to a third of the people who take them, according to a September 22, 2026 report from Men's Journal, which describes doctors turning to other approaches when first-line medications don't help. Men's Journal frames the roughly 1-in-3 figure as the reason clinicians are looking beyond the standard antidepressant playbook, though the outlet's summary does not specify the study or dataset behind the number.

This 1-in-3 figure lines up with how the field already defines the problem. Treatment-resistant depression is the clinical term for depression that does not improve after a patient has tried at least two different antidepressants at adequate doses for an adequate length of time. Patients in this category are exactly the population that ketamine clinics, psychiatrists, and specialty depression centers have spent the last several years trying to reach, since standard selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) were never designed with this subgroup in mind.

Men's Journal's brief summary does not detail every alternative the doctors it spoke with are now trying. But the shift it describes matches a trend already visible in psychiatric practice: a move toward options with a different mechanism of action than traditional antidepressants, including ketamine infusions, the FDA-approved nasal spray esketamine (brand name Spravato, approved in 2019 specifically for treatment-resistant depression), transcranial magnetic stimulation (TMS), and augmentation strategies that add a second medication rather than replacing the first.

What Treatment-Resistant Patients Should Ask Before Starting Ketamine Therapy

If antidepressants haven't worked for you, the practical question isn't whether alternatives exist, it's which provider can safely evaluate whether you're a candidate. Ketamine Clinics Online recommends readers treat the following as a starting checklist, not a guarantee of treatment:

• Documented medication history. Most reputable ketamine and esketamine providers, whether in-person or via telehealth, will ask for a record of which antidepressants you've tried, at what doses, and for how long. This history is what supports a treatment-resistant depression diagnosis and can also affect insurance coverage for esketamine specifically.
• A real screening process, not just a form. Ketamine is contraindicated or requires extra caution for people with certain cardiovascular conditions, uncontrolled hypertension, active substance use disorder, or a history of psychosis. A provider that skips a cardiovascular and psychiatric screen before the first session is cutting a corner that matters.
• Clarity on which product and route. Generic IV or intramuscular ketamine for depression is administered off-label, while Spravato is FDA-approved specifically for treatment-resistant depression and typically requires in-office administration with a two-hour monitoring period. Ask which one is being offered and why.
• A follow-up and maintenance plan. Ketamine's antidepressant effect is not typically permanent after a single course. Ask how the clinic structures induction sessions, maintenance dosing, and coordination with your existing psychiatrist or therapist, since ketamine is generally positioned as an addition to ongoing mental health care rather than a replacement for it.
• State-specific telehealth rules. Telehealth access to ketamine-adjacent care varies by state, and controlled-substance prescribing rules for telehealth have shifted several times in recent years. Confirm that a telehealth provider is licensed in your state and can legally prescribe or administer treatment there before you book an intake appointment.
• Out-of-pocket cost expectations. Generic ketamine infusions are usually not covered by insurance and are billed per session, while Spravato has a defined insurance pathway for patients who meet treatment-resistant depression criteria. Ask for a written cost estimate for a full induction course, not just the first visit.

The broader point in the Men's Journal report, that a meaningful share of patients need something beyond standard antidepressants, is not new information to anyone who has already cycled through two or three medications without relief. What matters for readers weighing next steps in 2026 is choosing a provider that treats that history as a starting point for a careful evaluation, not a reason to skip screening. This article is analysis based on the reported headline figure and general clinical background, not a review of the full Men's Journal article or its underlying data; readers should consult a licensed provider to evaluate their own treatment history and options.